There are papers reporting biomarkers to identify those rheumatoid arthritis patients with good response using sIL‐6R levels, in which serum sIL‐6R level, but not IL‐6 level, reportedly predicts clinical remission in patients with rheumatoid arthritis treated with IL‐6 receptor antibody (tocilizumab).30, 31. Here, IL6R is linked to rheumatoid arthritis.